Outcomes and responses to rituximab and/or LMP-TCs. Swimmer plots for ND patients (A) and patients with refractory disease (B), EFS (C), and OS (D) for ND patients and patients with R/R disease. The P value for the log-rank test between the ND patients and the patients with R/R disease is .024 for EFS and .049 for OS.